{"id":"somatostatin-octreotide","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Abdominal pain and cramping"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Gallstone formation (cholelithiasis)"},{"rate":"10-15","effect":"Hyperglycemia"},{"rate":"10-15","effect":"Injection site pain"}]},"_chembl":{"chemblId":"CHEMBL1680","moleculeType":"Protein","molecularWeight":"1019.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and surrounding tissues. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, while also causing vasoconstriction that reduces blood supply to tumors. The drug is used both therapeutically to control hormone-related symptoms and diagnostically in somatostatin receptor scintigraphy.","oneSentence":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:18.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (carcinoid syndrome, VIPomas, gastrinomas)"},{"name":"Acromegaly"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Acute pancreatitis"}]},"trialDetails":[{"nctId":"NCT05361668","phase":"PHASE2","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2022-04-22","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":36},{"nctId":"NCT07087054","phase":"PHASE3","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-19","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":141},{"nctId":"NCT05918302","phase":"PHASE3","title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-10-27","conditions":"Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms","enrollment":120},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":"Pancreatic Surgery","enrollment":655},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":259},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":"Neuroendocrine Tumors","enrollment":300},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":"Neuroendocrine Tumors","enrollment":78},{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":"Neuroendocrine Tumor","enrollment":33},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":69},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":"Small-for-Size Syndrome","enrollment":80},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT04997317","phase":"PHASE1, PHASE2","title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-21","conditions":"Meningioma","enrollment":18},{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":"Carcinoid Tumors","enrollment":43},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":"Congenital Hyperinsulinism","enrollment":3},{"nctId":"NCT03377660","phase":"","title":"Resection of the Esophagus and Subsequent Weight Loss","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2018-01-01","conditions":"Esophageal Cancer, Weight Gain, Eating Behavior","enrollment":30},{"nctId":"NCT06240039","phase":"NA","title":"Direct Versus Indirect Effect of Amino Acids on Hepatokines","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-02","conditions":"Non-Alcoholic Fatty Liver Disease, Obesity","enrollment":30},{"nctId":"NCT02385617","phase":"NA","title":"Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2014-01","conditions":"Esophageal Neoplasms, Stomach Neoplasms, Weight Loss","enrollment":20},{"nctId":"NCT02381249","phase":"NA","title":"The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2015-03","conditions":"Esophageal Neoplasms, Stomach Neoplasms, Weight Loss","enrollment":40},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage","enrollment":62},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT04276597","phase":"PHASE2","title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","status":"WITHDRAWN","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2020-03-04","conditions":"Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":"Liver Cirrhosis, Portal Vein, Venous Thrombosis","enrollment":475},{"nctId":"NCT04915144","phase":"PHASE2","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2023-01-15","conditions":"Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor","enrollment":""},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":"Neuroendocrine Tumors, Meningioma, Neuroblastoma","enrollment":39},{"nctId":"NCT02685709","phase":"PHASE3","title":"Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2016-02","conditions":"Acromegaly","enrollment":146},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":"Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour","enrollment":231},{"nctId":"NCT03158090","phase":"","title":"The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research","status":"RECRUITING","sponsor":"Ginkgo Leaf Center for Rare Disorders","startDate":"2017-12-15","conditions":"Acromegaly","enrollment":1965},{"nctId":"NCT04552847","phase":"PHASE2, PHASE3","title":"Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-07","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT03103009","phase":"PHASE1","title":"Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-03-22","conditions":"Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia","enrollment":1},{"nctId":"NCT01869725","phase":"PHASE2","title":"Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2013-04-01","conditions":"Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma","enrollment":68},{"nctId":"NCT03734627","phase":"","title":"Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2016-07-01","conditions":"Esophageal Cancer, Nutrition Disorders, Appetite Disorders","enrollment":40},{"nctId":"NCT01619865","phase":"PHASE1, PHASE2","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2012-02-21","conditions":"Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma","enrollment":223},{"nctId":"NCT02973204","phase":"","title":"Circulating Tumor Cells and Tumor DNA in HCC and NET","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-11","conditions":"Carcinoma, Hepatocellular, Neuroendocrine Tumors","enrollment":167},{"nctId":"NCT00001849","phase":"PHASE2","title":"New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1999-05-20","conditions":"Cushing Syndrome, Endocrine Disease","enrollment":95},{"nctId":"NCT04790708","phase":"NA","title":"Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)","status":"UNKNOWN","sponsor":"University Hospital of Ferrara","startDate":"2018-07-02","conditions":"Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT)","enrollment":250},{"nctId":"NCT03252353","phase":"PHASE3","title":"Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly","status":"UNKNOWN","sponsor":"Chiasma, Inc.","startDate":"2017-09-01","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT04194125","phase":"PHASE2","title":"Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer","status":"UNKNOWN","sponsor":"University of Warmia and Mazury","startDate":"2019-02-01","conditions":"Neuroendocrine Tumors","enrollment":25},{"nctId":"NCT04129255","phase":"PHASE2","title":"Octreotide LAR in the Induction of Immunologic Response in NENs Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2017-06-28","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT03883776","phase":"PHASE1","title":"Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-11","conditions":"Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT03197012","phase":"EARLY_PHASE1","title":"Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2017-07-01","conditions":"Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT02177773","phase":"PHASE1, PHASE2","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2014-06-23","conditions":"Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors","enrollment":300},{"nctId":"NCT01865760","phase":"NA","title":"Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-06","conditions":"Obesity, Hypoglycemia, Surgery","enrollment":33},{"nctId":"NCT03846180","phase":"","title":"Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2019-03-01","conditions":"Variceal Hemorrhage, Cirrhosis, Liver, Kidney Injury","enrollment":1682},{"nctId":"NCT03057509","phase":"PHASE1","title":"A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-11","conditions":"Small Bowel Carcinoid Tumor","enrollment":""},{"nctId":"NCT03812939","phase":"","title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Gastric NET","enrollment":30},{"nctId":"NCT01370161","phase":"NA","title":"Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2011-07","conditions":"Decompensated Cirrhosis, Bleeding Varices","enrollment":132},{"nctId":"NCT02874326","phase":"PHASE2","title":"Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia","enrollment":15},{"nctId":"NCT00966355","phase":"PHASE4","title":"Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding","status":"COMPLETED","sponsor":"Korea University","startDate":"2006-09","conditions":"Variceal Bleeding, Cirrhosis","enrollment":1034},{"nctId":"NCT01677910","phase":"PHASE3","title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2013-01-08","conditions":"Carcinoid Syndrome","enrollment":135},{"nctId":"NCT02217800","phase":"PHASE2","title":"The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2013-11","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT01377246","phase":"PHASE3","title":"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-05","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":100},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":"Neuroendrocrine Tumors, Meningioma, Neuroblastoma","enrollment":""},{"nctId":"NCT01412424","phase":"PHASE3","title":"Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2012-03","conditions":"Acromegaly","enrollment":155},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT02359500","phase":"PHASE1","title":"68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)","status":"TERMINATED","sponsor":"Lale Kostakoglu","startDate":"2014-12","conditions":"Neuroendocrine Tumors, Carcinoid Tumors","enrollment":71},{"nctId":"NCT00376064","phase":"PHASE4","title":"Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Acromegaly","enrollment":20},{"nctId":"NCT01618513","phase":"PHASE4","title":"Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Acromegaly","enrollment":84},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT00049023","phase":"PHASE1","title":"Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors","status":"COMPLETED","sponsor":"O'Dorisio, M S","startDate":"2002-01","conditions":"Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor","enrollment":27},{"nctId":"NCT02111044","phase":"PHASE2","title":"Phase II Study With ITF2984 in Acromegalic Patients","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2014-04","conditions":"Acromegaly","enrollment":48},{"nctId":"NCT01755182","phase":"PHASE3","title":"Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors","status":"TERMINATED","sponsor":"National Cancer Institute, Naples","startDate":"2013-07","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT02631616","phase":"PHASE1","title":"Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2016-02","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT00227773","phase":"PHASE2","title":"Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma","enrollment":""},{"nctId":"NCT02012166","phase":"PHASE1","title":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00978211","phase":"PHASE2","title":"DOTA-TOC in Metastasized Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"1997-09","conditions":"Neuroendocrine Tumors","enrollment":1499},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT02311608","phase":"","title":"Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-02","conditions":"Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage","enrollment":1320},{"nctId":"NCT01029275","phase":"NA","title":"Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2005-01","conditions":"Acromegaly","enrollment":89},{"nctId":"NCT00002947","phase":"PHASE1","title":"Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer","status":"TERMINATED","sponsor":"Yale University","startDate":"1996-10","conditions":"Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor","enrollment":35},{"nctId":"NCT00510224","phase":"PHASE2","title":"Sandostatin for Patients With Androgen Independent Prostate Cancer","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2007-07","conditions":"Prostate Cancer","enrollment":13},{"nctId":"NCT00765323","phase":"PHASE3","title":"Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2008-09","conditions":"Acromegaly","enrollment":169},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT01871844","phase":"PHASE1","title":"ITF2984 Repeated Doses Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2012-01","conditions":"Healthy Male Volunteers","enrollment":46},{"nctId":"NCT00006370","phase":"PHASE2","title":"Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2000-07","conditions":"Breast Cancer, Lung Cancer","enrollment":275},{"nctId":"NCT00006368","phase":"PHASE1","title":"Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"1998-01","conditions":"Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor","enrollment":60},{"nctId":"NCT00309283","phase":"PHASE3","title":"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2006-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":78},{"nctId":"NCT00652379","phase":"NA","title":"Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2008-06","conditions":"Acromegaly, Insulin Resistance, Impaired Glucose Tolerance","enrollment":18},{"nctId":"NCT00222092","phase":"","title":"Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers","status":"COMPLETED","sponsor":"University of Ioannina","startDate":"2005-09","conditions":"Post-ERCP Acute Pancreatitis","enrollment":300},{"nctId":"NCT01267669","phase":"NA","title":"A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2005-11","conditions":"Acute Bleeding Esophageal Varices, Portal Hypertension, Cirrhosis","enrollment":61},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT01188733","phase":"PHASE1, PHASE2","title":"Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-06","conditions":"Cirrhosis, Portal Hypertension, Esophageal Varices","enrollment":39},{"nctId":"NCT00005906","phase":"PHASE2","title":"Treatment With Octreotide in Patients With Lymphangioleiomyomatosis","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2000-06","conditions":"Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions","enrollment":4},{"nctId":"NCT00990535","phase":"PHASE2","title":"High Dose Somatostatin Analogues in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Federico II University","startDate":"2006-01","conditions":"Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms","enrollment":28},{"nctId":"NCT00495846","phase":"PHASE2, PHASE3","title":"GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Federico II University","startDate":"2007-04","conditions":"Advanced Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT00703079","phase":"","title":"Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly","status":"COMPLETED","sponsor":"Federico II University","startDate":"1997-01","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":"Acromegaly","enrollment":10},{"nctId":"NCT00001860","phase":"PHASE2","title":"Sandostatin LAR Depot vs. Surgery for Treating Acromegaly","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1999-08","conditions":"Acromegaly, Pituitary Neoplasm","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Somatostatin (octreotide)","genericName":"Somatostatin (octreotide)","companyName":"University Hospital Freiburg","companyId":"university-hospital-freiburg","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors. Used for Neuroendocrine tumors (carcinoid syndrome, VIPomas, gastrinomas), Acromegaly, Variceal bleeding in portal hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}